Last reviewed · How we verify
Placebo (for Ramucirumab)
Placebo is an inert substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo (for Ramucirumab) |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as a control comparator in clinical trials and contains no active pharmaceutical ingredient. It is used to establish the efficacy and safety profile of the active drug (in this case, Ramucirumab) by comparison against a non-therapeutic baseline. Any observed effects are attributed to natural disease progression, regression to the mean, or the placebo effect rather than direct drug action.
Approved indications
Common side effects
Key clinical trials
- A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (PHASE2)
- A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM (PHASE2)
- Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer (PHASE3)
- A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (PHASE3)
- Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma (PHASE3)
- A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy (PHASE3)
- A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (PHASE3)
- A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Ramucirumab) CI brief — competitive landscape report
- Placebo (for Ramucirumab) updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI